Photo courtesy of VelosBio.
VelosBio’s licensed its antibody-drug conjugate ROR1 from UCSD cancer researcher Thomas Kipps.

Photo courtesy of VelosBio. VelosBio’s licensed its antibody-drug conjugate ROR1 from UCSD cancer researcher Thomas Kipps.

Pharmaceutical giant Merck, will pay $2...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99